Since the activation of the Akt pathway is key for the development of resistance to cisplatin in ovarian cancer patients (24), these results prompted us to evaluate the effect of this peptide on the sensitization of ovarian cancer cells to cisplatin. The gene discussed is AKT1; the disease is ovarian cancer.